TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60~* Scheduled for a cardiac surgical procedure with planned post-operative admission to the CSICU for ≥ 24 hours~* Scheduled same day surgical admission~Exclusion Criteria:~* Blind, deafness or the inability to speak English~* Greater than 2 days of ICU admission in the month preceding the current surgical procedure~* Renal and liver failure requiring dialysis or Child-Pugh score \> 5~* Follow-up difficulties (i.e. active substance abuse, psychotic disorder, homelessness)~* Previous cardiac surgery within 1 year of surgical procedure~* Allergy to dexmedetomidine~* Chronic therapy with benzodiazepines and/or antipsychotics~* Severe deficit due to structural or anoxic brain damage~* Surgical procedure requiring total circulatory arrest~Objective Drop Criteria~* Scheduled for a second surgical procedure during hospital stay~* Post-operative intubation \> 12 hours

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dexmedetomidine-induced sleep (Type: EXPERIMENTAL): Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Participant is ≥18 years of age at the time of informed consent.~2. Participant has AHA, and is being treated/was treated with Obizur.~3. Participant or the participant's legally authorized representative is willing and able to provide informed consent, unless informed consent is not required~Exclusion Criteria:~1. Participant has a known anaphylactic reaction to the active substance, to any of the excipients, or to hamster protein.~2. Participant has a concomitant bleeding disorder(s) other than acquired hemophilia A (AHA).~3. Participant has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OBIZUR - Prospective Participants (Type: None): Participants enrolled and treated with Obizur after the prospective study start date
- OBIZUR - Retrospective Participants (Type: None): Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Male or female patients ≥18 years of age~* Non-diabetic patients must have MSSBP of ≥140 mmHg and/or MSDBP ≥90 mmHg at Visits 1 and 2. Diabetic patients must have MSSBP ≥130 mmHg and/or MSDBP ≥80 mmHg at Visits 1 and 2~* Patients treated with monotherapy at a dose considered as adequate by the investigator for a minimum of two months prior to Visit 1~Exclusion criteria~* Known or suspected contraindications, including history of allergy to ARBs, CCB, thiazides or to drugs with similar chemical structure.~* MSSBP ≥180 mmHg and/or MSDBP ≥110 mmHg (MSSBP ≥160 mmHg and/or MSDBP ≥100 mmHg for diabetic patients) at any time between Visit 1 and Visit 2.~* Evidence of a secondary form of hypertension, to include coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, or pheochromocytoma.~* Known Keith-Wagener grade III or IV hypertensive retinopathy.~* Other exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 to 60 years of age.~* Meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for schizophrenia (paranoid type, disorganized type, catatonic type, or undifferentiated type) based on a Structured Clinical Interview for DSM-IV (SCID).~* Total Positive and Negative Syndrome Scale (PANSS) score ≥ 80 and ≤ 120.~* Diagnosis of schizophrenia for at least 1 year.~Exclusion Criteria:~* Abnormalities on physical examination or abnormal vital signs, electrocardiogram, or clinical laboratory values.~* First episode of psychosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once a day for 6 weeks.
- Cariprazine 1.5 mg (Type: EXPERIMENTAL): Participants received cariprazine 1.5 mg orally once a day for 6 weeks.
- Cariprazine 3.0 mg (Type: EXPERIMENTAL): Participants received cariprazine 3.0 mg orally once a day for 6 weeks.
- Cariprazine 4.5 mg (Type: EXPERIMENTAL): Participants received cariprazine 4.5 mg orally once a day for 6 weeks.
- Risperidone 4.0 mg (Type: ACTIVE_COMPARATOR): Participants received risperidone 4.0 mg orally once a day for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BiliCam Clinical Validation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newborn born at ≥ 35 weeks gestation~* Parent speaks and reads English~* Parent provides written informed consent~Exclusion Criteria:~* previous or ongoing treatment with phototherapy for hyperbilirubinemia~* Medical or other complications that preclude completion of the study

- Gender: ALL
- Minimum Age: 0 Hours
- Maximum Age: 191 Hours
- Healthy Volunteers: t

Study Arms:
- Newborns (Type: EXPERIMENTAL): Newborns will be enrolled in the study in 2 different ways. At Staged Enrollment sites, newborns will be enrolled when they are \< 48 hours old. These newborns will have a study visit when they are 48 - 167 hours old. At the study visit, a BCB will be determined and blood will be drawn for study purposes for a TSB level. At Simultaneous Enrollment sites, newborns will be enrolled and have a study visit at the time of a blood draw (+/- 2 hours) for a TSB level that is being obtained for clinical purposes. Newborns will be 0-191 hours old.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Paramedics or reliable witnesses verify 5 minutes of either continuous seizure activity or of repeated convulsive seizure activity where the patient does not regain consciousness (operationally defined as meaningful speech or obeying commands) between seizures.~* Patient is still seizing at the time of paramedic treatment with study medications.~* Estimated weight equal to or greater than 13 kg.~* Subject to be transported to a RAMPART participating hospital.~Exclusion Criteria:~* Major trauma as the precipitant of the seizure~* Hypoglycemia (as defined by local EMS protocol or a glucose \< 60 mg/dL)~* Known allergy to midazolam or lorazepam~* Cardiac arrest or heart rate (HR) \<40 beats per minute~* Sensitivity to benzodiazepines~* Medical alert tag marked with RAMPART declined~* Prior treatment of this seizure with diazepam autoinjector as part of another study~* Known pregnancy~* Prisoners

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intramuscular (IM) anticonvulsant (Type: ACTIVE_COMPARATOR): This group gets active treatment with an anticonvulsant by the intramuscular route of administration.
- Intravenous (IV) anticonvulsant (Type: ACTIVE_COMPARATOR): This group gets active treatment with an anticonvulsant by the intravenous route of administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of asthma for a period of at least 6 months prior to Visit 1 with current asthma severity ≥ step 4 (GINA 2017).~* Patients who had used ICS/LABA combinations for asthma for at least 3 months and at stable medium or high dose of ICS/LABA for at least 1 month prior to Visit 1.~* Patients were required to be symptomatic at screening despite treatment with medium or high stable doses of ICS/LABA as defined by ACQ-7 score ≥ 1.5 at visits 101 and 201 (randomization visit).~* Patients with history of at least one severe asthma exacerbation which required medical care from a physician, emergency room visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1 and required systemic corticosteroid treatment for at least 3 days including physician guided self-management treatment with oral corticosteroids as part of written asthma action plan.~* Pre-bronchodilator FEV1 of \< 85 % of the predicted normal value for the patient after withholding bronchodilators prior to spirometry at both Visit 101 and Visit 201.~* Patients who demonstrated an increase in FEV1 of ≥ 12% and 200 ml.~Exclusion Criteria:~* Patients who had a smoking history of greater than 20 pack years.~* Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).~* Patients who had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening).~* Patients treated with a LAMA for asthma within 3 months prior to Visit 1.~* Patients who had a respiratory tract infection or clinical significant asthma worsening as defined by Investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit 201.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVM149 150/50/80 μg (Type: EXPERIMENTAL): QVM149 150/50/80 μg o.d. delivered via Concept1
- QVM149 150/50/160 μg (Type: EXPERIMENTAL): QVM149 150/50/160 μg o.d. delivered via Concept1
- Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg (Type: ACTIVE_COMPARATOR): Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* 30-75 years of age~* less than 1% fluctuation in HbA1c over 3 months~* women must be on contraception~* HbA1c 6-9%~* willingness to sign approved consent form~Exclusion Criteria:~* Nursing mothers, pregnant women (excluded by a negative pregnancy test).~* Subjects requiring insulin therapy (\>20 units/day) and can not be converted to sulfonylurea therapy without loss of diabetes control.~* Patients with a history of drug or alcohol dependence in the last 5 years~* Patients with pre-existing cardiovascular disease including coronary artery disease, heart attack, heart failure, abnormal heart rhythms, structural abnormalities and valve disease, peripheral vascular disease and uncontrolled high blood pressure.~* Patients with a history of high cholesterol requiring therapy.~* Patients with severe systemic disease other than diabetes which has as a recognized complication neuropathy~* Patients currently taking drugs which act on the blood vessels (for example for hypertension)~* Patients taking antidepressants, or other drugs or medications known to interfere with the uptake or metabolism of catecholamines (stress hormones)~* Patients with poor renal function or have significant liver disease~* Patients with a history of previous kidney, pancreas or cardiac transplantation.~* Patients with a history of severe hypoglycemia which required the assistance of a third party or ketoacidosis requiring hospital admission within the last 3 months.~* Patients with lung disease for example resulting from chronic obstructive airways disease.~* Patients with abnormal thyroid function tests.~* Patients having taken other systemic investigational drugs (especially for neuropathy) or initiating a new or experimental insulin delivery device within 3 months of starting the study.~* Patients with a history of allergic reactions to multiple drugs or biological products.~* Obese patients (BMI greater than 35).~* Patients who refuse to sign the informed consent.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient of age \>18 years and \<65 years~* Victim of direct experience trauma (accident or physical aggression)~* Presence of an ASD between D3 and D7 after the trauma according to DSM V criteria~Exclusion Criteria:~* Contra-indication to prazosin: orthostatic hypotension, right heart failure, other hypotensive therapy, 5-phosphodiesterase inhibitors (sildenafil) or diuretic, history of syncope or severe unexplained faintness, hypersensitivity known to quinazolines.~* Alcohol and / or drug use at the time of the trauma~* History of psychotic disorder~* Suicidal risk defined by a score ≥ 2 on the Suicidal Ideas Item of the Beck Depression Inventory (BDI)~* Protected or vulnerable Major~* Persistence of a life threatening injury at D3~* Sexual assault~* Only moderate head trauma can be included and therefore excluded patients with loss of consciousness greater than 30 minutes, Glasgow score less than 13, post-traumatic amnesia greater than 24 hours (Ruff et al., 2009) .~* Prescription of morphine or morphine derivative in progress~* Pregnancy or breastfeeding period~* Lack of effective contraception in a woman susceptible to childbearing~* Known hepatic dysfunction~* Narcolepsy (Gelineau's disease)~* Cardiac or vascular history including coronary artery disease~* Strict low-sodium diet

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prazosin, ALPRESS® LP 2,5 et 5 mg (Type: EXPERIMENTAL): Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 18 through 49 years and in good health by history, physical exam, and labs~* Weight greater than or equal to (\>=) 45 kilogram (kg) and less than or equal to (\<=) 110 kg at Screening~* Written informed consent prior to performing any protocol related procedures, including Screening evaluations~* Ability to complete the Follow-up period of 360 days~Key Exclusion Criteria:~* Acute illness including fever \>= 99.5 Fahrenheit (°F) on day of dosing~* Any drug therapy within 7 days prior to Day 1 (except contraceptives)~* Receipt of any investigational drug therapy within 120 days prior to investigational product dosing through 360 days after investigational product dosing~* Previous receipt of a monoclonal antibody (mAb)~* Pregnant or nursing mother~* Concurrent enrollment in another interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- MEDI8897 300 milligram (mg) Intravenous (IV) (Type: EXPERIMENTAL): Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
- MEDI8897 1000 mg IV (Type: EXPERIMENTAL): Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
- MEDI8897 3000 mg IV (Type: EXPERIMENTAL): Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
- MEDI8897 100 mg Intramuscular (IM) (Type: EXPERIMENTAL): Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
- MEDI8897 300 mg IM (Type: EXPERIMENTAL): Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent prior to participation~2. Female and male patients age ≥ 18 years~3. Patients with T2D diagnosis~4. Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)~5. Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1~Exclusion Criteria:~1. Patients age \< 18 years~2. Patients with diagnosis of other types of diabetes than T2D~3. Patients who do not provide written consent to the terms of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with Diabetes Mellitus, Type 2 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete